Pharmafile Logo

Sylvant

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

- PMLiVE

SMC backtracks on Janssen’s multiple myeloma treatment Darzalex

Will now recommend the first-in-class treatment after securing a discount

- PMLiVE

Janssen’s Imbruvica fails to win NICE backing in lymphoma

But the agency recommends it on the CDF for another type of cancer

- PMLiVE

Janssen wins European approval for Symtuza

European Commission approves the drug to treat HIV-1

- PMLiVE

Janssen launches UK blood cancer awareness campaign

The pharma group join forces with designer to set up ‘giant’ names in London

EphMRA 2017 round up

We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands.

Research Partnership

- PMLiVE

Executional Excellence – creating work that works

In the Executional Excellence edition of Perspective magazine, we explore topics around the ‘executional excellence’ theme – creating work that works.

Blue Latitude Health

- PMLiVE

J&J’s Jane Griffiths named global head of Actelion

Appointment will effect once Swiss biotech's acquisition is completed

- PMLiVE

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

Lucid Group Communications Limited

Shire Basingstoke

Shire finally bags EU approval for rare disease drug Natpar

Becomes first licenced treatment for hypoparathyroidism in Europe

Blending medical and digital for effective rare disease campaigns

The fundamentals of building a collaborative medical and digital team

Using service design to improve patients’ quality of life

Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links